The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma

George Kabalka, Trent L. Nichols, Gary T. Smith, Laurence F. Miller, Mohammad K. Khan, Paul M. Busse

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Centers in Japan and the United States are extending boron neutron capture therapy (BNCT) to the treatment of malignant melanoma (MM). Positron emission tomography (PET) has been used to image glioblastoma multiforme with 18F-boronophenylalanine (18F-BPA) for the purpose of generating 10B distribution maps. These distribution maps can be used to improve the BNCT treatment planning. 18F-BPA was given to a patient with widely metastatic MM involving the thorax and brain. 18F-BPA PET scans of the chest and the head were obtained and compared to the computed tomograms (CT) and magnetic resonance (MR) images. The lung metastases seen on the chest CT images and intracranial metastases seen on CT and MR images were correlated with the PET images. The PET images clearly identified a brain lesion that was difficult to identify on MR and CT images. The 18F-BPA lung and peri-oral mucous gland activity was intense indicating a relatively high concentration of BPA. The intensity seen in the peri-oral mucous glands is consistent with the experiences in the BNCT clinical trials. These results have implications in the use of BNCT outside of the cranium. The PET images allow the generation of treatment plans that are consistent with the clinical findings. PET imaging with 18F-BPA can be used to identify potential tumors that may be amenable to BNCT and to improve treatment plans prior to BNCT.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalJournal of Neuro-Oncology
Volume62
Issue number1-2
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Boron Neutron Capture Therapy
Positron-Emission Tomography
Melanoma
Magnetic Resonance Spectroscopy
Thorax
Therapeutics
Neoplasm Metastasis
Lung
Brain
Glioblastoma
Skull
Japan
Head
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. / Kabalka, George; Nichols, Trent L.; Smith, Gary T.; Miller, Laurence F.; Khan, Mohammad K.; Busse, Paul M.

In: Journal of Neuro-Oncology, Vol. 62, No. 1-2, 01.03.2003, p. 187-195.

Research output: Contribution to journalArticle

Kabalka, George ; Nichols, Trent L. ; Smith, Gary T. ; Miller, Laurence F. ; Khan, Mohammad K. ; Busse, Paul M. / The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. In: Journal of Neuro-Oncology. 2003 ; Vol. 62, No. 1-2. pp. 187-195.
@article{30b4c87ec14d4610b9850d24f0963a5c,
title = "The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma",
abstract = "Centers in Japan and the United States are extending boron neutron capture therapy (BNCT) to the treatment of malignant melanoma (MM). Positron emission tomography (PET) has been used to image glioblastoma multiforme with 18F-boronophenylalanine (18F-BPA) for the purpose of generating 10B distribution maps. These distribution maps can be used to improve the BNCT treatment planning. 18F-BPA was given to a patient with widely metastatic MM involving the thorax and brain. 18F-BPA PET scans of the chest and the head were obtained and compared to the computed tomograms (CT) and magnetic resonance (MR) images. The lung metastases seen on the chest CT images and intracranial metastases seen on CT and MR images were correlated with the PET images. The PET images clearly identified a brain lesion that was difficult to identify on MR and CT images. The 18F-BPA lung and peri-oral mucous gland activity was intense indicating a relatively high concentration of BPA. The intensity seen in the peri-oral mucous glands is consistent with the experiences in the BNCT clinical trials. These results have implications in the use of BNCT outside of the cranium. The PET images allow the generation of treatment plans that are consistent with the clinical findings. PET imaging with 18F-BPA can be used to identify potential tumors that may be amenable to BNCT and to improve treatment plans prior to BNCT.",
author = "George Kabalka and Nichols, {Trent L.} and Smith, {Gary T.} and Miller, {Laurence F.} and Khan, {Mohammad K.} and Busse, {Paul M.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1023/A:1023236921638",
language = "English (US)",
volume = "62",
pages = "187--195",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma

AU - Kabalka, George

AU - Nichols, Trent L.

AU - Smith, Gary T.

AU - Miller, Laurence F.

AU - Khan, Mohammad K.

AU - Busse, Paul M.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Centers in Japan and the United States are extending boron neutron capture therapy (BNCT) to the treatment of malignant melanoma (MM). Positron emission tomography (PET) has been used to image glioblastoma multiforme with 18F-boronophenylalanine (18F-BPA) for the purpose of generating 10B distribution maps. These distribution maps can be used to improve the BNCT treatment planning. 18F-BPA was given to a patient with widely metastatic MM involving the thorax and brain. 18F-BPA PET scans of the chest and the head were obtained and compared to the computed tomograms (CT) and magnetic resonance (MR) images. The lung metastases seen on the chest CT images and intracranial metastases seen on CT and MR images were correlated with the PET images. The PET images clearly identified a brain lesion that was difficult to identify on MR and CT images. The 18F-BPA lung and peri-oral mucous gland activity was intense indicating a relatively high concentration of BPA. The intensity seen in the peri-oral mucous glands is consistent with the experiences in the BNCT clinical trials. These results have implications in the use of BNCT outside of the cranium. The PET images allow the generation of treatment plans that are consistent with the clinical findings. PET imaging with 18F-BPA can be used to identify potential tumors that may be amenable to BNCT and to improve treatment plans prior to BNCT.

AB - Centers in Japan and the United States are extending boron neutron capture therapy (BNCT) to the treatment of malignant melanoma (MM). Positron emission tomography (PET) has been used to image glioblastoma multiforme with 18F-boronophenylalanine (18F-BPA) for the purpose of generating 10B distribution maps. These distribution maps can be used to improve the BNCT treatment planning. 18F-BPA was given to a patient with widely metastatic MM involving the thorax and brain. 18F-BPA PET scans of the chest and the head were obtained and compared to the computed tomograms (CT) and magnetic resonance (MR) images. The lung metastases seen on the chest CT images and intracranial metastases seen on CT and MR images were correlated with the PET images. The PET images clearly identified a brain lesion that was difficult to identify on MR and CT images. The 18F-BPA lung and peri-oral mucous gland activity was intense indicating a relatively high concentration of BPA. The intensity seen in the peri-oral mucous glands is consistent with the experiences in the BNCT clinical trials. These results have implications in the use of BNCT outside of the cranium. The PET images allow the generation of treatment plans that are consistent with the clinical findings. PET imaging with 18F-BPA can be used to identify potential tumors that may be amenable to BNCT and to improve treatment plans prior to BNCT.

UR - http://www.scopus.com/inward/record.url?scp=0038707483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038707483&partnerID=8YFLogxK

U2 - 10.1023/A:1023236921638

DO - 10.1023/A:1023236921638

M3 - Article

C2 - 12749713

AN - SCOPUS:0038707483

VL - 62

SP - 187

EP - 195

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -